The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs

@article{Buscemi2007TheEA,
  title={The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs},
  author={Nina Buscemi and B. Vandermeer and Carol Friesen and Liza Bialy and Michelle Tubman and Maria B. Ospina and Terry P Klassen and Manisha Witmans},
  journal={Journal of General Internal Medicine},
  year={2007},
  volume={22},
  pages={1335-1350}
}
BackgroundHypnotics have a role in the management of acute insomnia; however, the efficacy and safety of pharmacological interventions in the management of chronic insomnia is unclear. [] Key MethodData SourcesTwenty-one electronic databases were searched, up to July 2006.Study SelectionRandomized double-blind, placebo-controlled trials were eligible. Quality was assessed using the Jadad scale. Data were pooled using the random effects model.

Figures and Tables from this paper

Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration

Compared with placebo, Z drugs produce slight improvements in subjective and polysomnographic sleep latency, especially with larger doses and regardless of type of drug.

Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.

Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: A randomized placebo-controlled pilot study

Chamomile could provide modest benefits of daytime functioning and mixed benefits on sleep diary measures relative to placebo in adults with chronic primary insomnia, but further studies in select insomnia patients would be needed to investigate these conclusions.

Efficacy and Safety of Electroacupuncture for Insomnia Disorder: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial

Ten sessions of electroacupuncture can improve the sleep quality of patients with insomnia without serious adverse effects and can be recommended as an effective, safe, and well-tolerated intervention.

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.

Lemborexant was ranked highest of the treatments studied on 3 out of the 4 objectively measured insomnia efficacy outcomes, with a safety profile broadly similar to other insomnia treatments, and the treatment effect was similar in older and adult populations.

Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia

The aim of this study was to evaluate the efficacy and safety of ramelteon 4, 8, 16 or 32 mg and placebo in Japanese patients with chronic insomnia using a randomized, double-blind, five-period
...

References

SHOWING 1-10 OF 36 REFERENCES

Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy.

Benzodiazepines and zolpidem produced reliable improvements in commonly measured parameters of sleep in patients with chronic insomnia, and presented challenges for developing evidence-based guidelines for the use of hypnotics in the management of chronic insomnia.

Meta-analysis of benzodiazepine use in the treatment of insomnia.

The use of benzodiazepines in the treatment of insomnia is associated with an increase in sleep duration, but this is countered by a number of adverse effects and additional studies evaluating the efficacy of nonpharmacological interventions would be valuable.

Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits

Improvements in sleep with sedative use are statistically significant, but the magnitude of effect is small, and the increased risk of adverse events is statistically significant and potentially clinically relevant in older people at risk of falls and cognitive impairment.

Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia.

Overall, behavior therapy and pharmacotherapy produce similar short-term treatment outcomes in primary insomnia.

Ten-year trends in the pharmacological treatment of insomnia.

Overall pharmacological treatment of insomnia has decreased substantially since 1987 although surveys indicate a stable or increasing prevalence of sleep disturbance.

Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies.

There are differences among the rapidly eliminated hypnotics with respect to tolerance and rebound insomnia suggesting that, in addition to short elimination half-life, other pharmacological properties are implicated in the mechanisms underlying these side-effects.

Prevalence, burden, and treatment of insomnia in primary care.

While insomnia was associated with depressive disorder and chronic medical illness, adjustment for these factors only partially accounted for the association of insomnia with disability and with health care utilization.

Comparative efficacy of newer hypnotic drugs for the short‐term management of insomnia: a systematic review and meta‐analysis

To compare the clinical effectiveness of zaleplon, zolpidem or zopiclone with either benzodiazepines licensed and approved for use in the UK for the short‐term management of insomnia or with each other, a comparison study is conducted.

Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years.

Data do not support a model of incident insomnia caused by the aging process per se, but chronic disease, depressed mood, physical disability, poor perceived health, widowhood, and use of sedatives are associated with development and remission of insomnia symptoms.